Explore our library of presentations, brochures and relevant publications
Learn more about how our CRISPR-derived A1AT cells can reproducibly recapitulate the disease phenotype in-a-dish, revealing increased polymeric alpha-1-antitrypsin formation and accumulation compared to their isogenic controls.
Abridged case studies
Learn more about the key aspects and key data sets of our in-house models
In this webinar you will discover how iPSC derived cells can be used to advance the efficiency and efficacy of disease modeling. The webinar will cover topics including functionality, modeling disease phenotypes, therapeutic modalities and delivery and efficacy.
In this white paper you will discover how human induced pluripotent stem cell derived hepatocyte-like cells (HLCs) have the potential to act as an ideal model for the study of liver diseases, combining the expansion capacity and phenotypic stability of hepatoma cell lines with the functionality and normal karyotype of primary hepatocytes.
Within the white paper you will also learn more about DefiniGEN’s iPSC-derived HLC platform which is capable of screening candidate therapeutics with high accuracy and reproducibility.
OptiDIFF technology is firmly rooted in the rigorous scientific studies of DefiniGEN founder Ludovic Vallier, PhD. Prof. Vallier and his lab pioneered the ability to differentiate human stem cells into hepatocytes, and the scientists at DefiniGEN have turned this work into a streamlined and scalable commercial process.